An inducer’s effect can evolve during treatment rather than remaining fixed after its first dose.
A physiologically based model described carbamazepine and its active epoxide metabolite, including autoinduction. It evaluated interaction predictions involving several drugs, including alprazolam, against published concentration data.
The model was assembled from multiple studies and relied on assumptions about enzyme processes and exposure. Good overall prediction performance does not guarantee an exact individual alprazolam concentration or an identical interaction at every treatment stage.
Document when carbamazepine was started, changed or stopped as well as the benzodiazepine dose. Do not treat a modeled interaction ratio as a measured finding in the patient. The work supports attention to time-dependent metabolism and model uncertainty, not precise retrospective dose reconstruction from a single result.
Source: PMC7922031, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Valerian Interaction Claims Need Separate Pharmacokinetic and Sedative Evidence.